EmblemHealth

Genetic Testing for Statin-Induced Myopathy

Last Review Date: November 9, 2018	Number: MG.MM.LA.23C3

Medical Guideline Disclaimer

Definitions

Statin-induced myopathy is a side effect that occurs in susceptible individuals taking statin for the treatment of hypercholesterolemia and coronary artery disease. Inherited variations on the SLCO1B1 gene appear to increase the risk of statin-induced myopathy and reduce effectiveness of statin therapy. Statin-induced myopathy is categorized into statin-induced myalgia, statin-induced myositis and statin-induced rhabdomyolysis.

Guideline

Genetic testing of variants in the SLCO1B1 gene to identify individuals at increased risk of statin-induced myopathy is considered investigational and not medically necessary.

Applicable Procedure Codes

81400	Molecular pathology procedure, Level 1 (eg, identification of single germline variant [eg, SNP] by techniques such as restriction enzyme digestion or melt curve analysis) (Revision eff. 01/01/2018)

References

1. Brunham LR, Lansberg PJ, Zhang L et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin. Pharmacogenomics J 2012; 12(3):233-7. http://www.nature.com/tpj/journal/v12/n3/full/tpj201092a.html. Accessed November 9, 2018.
2. Drobny M, Pullmann R, Odalos I, et al. Incidence of skeletal muscle disorders after statins' treatment: consequences in clinical and EMG picture. Neuro Endocrinol Lett. 2014; 35(2):123-128.
3. Santos, P., Soares, R., Nascimento, R. M., Machado-Coelho, G., Mill, J. G., Krieger, J. E., et al. (2011). SLCO1B1 rs4149056 polymorphism associated with statin-induced myopathy is differently distributed according to ethnicity in the Brazilian general population: Amerindians as a high risk ethnic group. BMC Medical Genetics, 12:136. (Level 2 Evidence)
4. SEARCH Collaborative Group, Link E, Parish S et al. SLCO1B1 variants and statin-induced myopathy--a genomewide study. N Engl J Med 2008; 359(8):789-99. http://www.nejm.org/doi/full/10.1056/NEJMoa0801936#t=articleBackground. Accessed November 9, 2018.

5. Stewart A. SLCO1B1 polymorphisms and statin-induced myopathy. PLoS Curr. 2013; 5. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3871416/?report=printable. Accessed November 9, 2018.
6. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014; 129(25 Suppl 2):S1-S45.https://www.ahajournals.org/doi/abs/10.1161/01.cir.0000437738.63853.7a. Accessed November 9, 2018.
7. Voora, D., Shah, S. H., Spasojevic, I., Ali, S., Reed, C. R., Salisbury, B. A., et al. (2009). The SLCO1B1*5 genetic variant is associated with statin-induced side effects. Journal of the American College of Cardiology, 54 (17), 1609-1616. (Level 2 Evidence - Industry sponsored)
8. Wilke RA, Ramsey LB, Johnson SG et al. The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clin Pharmacol Ther 2012; 92(1):112-7. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384438/. Accessed November 9, 2018.
9. Wilke, R. A., Ramsey, L. B., Johnson, S. G., Maxwell, W. D., McLeod, H. L., Voora, D., et al. (2012). The Clinical Pharmacogenomics Implementation Consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy. Clinical Pharmacology & Therapeutics, 92 (1), 112-117.
10. Woolley T, Canoniero M, Conroy W, et al. Institute for Clinical Systems Improvement (ICSI). Lipid Management in Adults. Updated Feb. 2017. https://www.icsi.org/_asset/qz5ydq/LipidMgmt-Interactive1111.pdf. Accessed November 9, 2018.
11. Specialty matched clinical peer review.